Ultragenyx is reducing its workforce by 20% and discontinuing several dr-g development projects. These measures are intended to significantly decrease the company's annual research and development spending. The company aims to achieve profitability in 2027. This strategic shift involves focusing on commercial products and reducing early-stage research. Ultragenyx will now employ approximately 1,000 staff.
Novato, California
https://www.fiercebiotech.com/biotech/ultragenyx-shrinks-workforce-and-axes-assets-halve-rd-spend